| Hypothalamic activation in spontaneous migraine attacks. | |
| | |
MedLine Citation:
|
PMID: 18052951 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Migraine sufferers experience premonitory symptoms which suggest that primary hypothalamic dysfunction is a likely trigger of the attacks. Neuroendocrine and laboratory data also support this hypothesis. To date, positron emission tomography (PET) scans of migraine sufferers have demonstrated activation of brainstem nuclei, but not of the hypothalamus. OBJECTIVE: To record cerebral activations withH2 15OPET during spontaneous migraine without aura attacks. METHODS: We scanned 7 patients with migraine without aura (6 females and 1 male) in each of 3 situations: within 4 hours of headache onset, after headache relief by sumatriptan injection (between the fourth and the sixth hour after headache onset), and during an attack-free period. RESULTS: During the headache we found not only significant activations in the midbrain and pons, but also in the hypothalamus, all persisting after headache relief by sumatriptan. CONCLUSION: Hypothalamic activity, long suspected by clinical and experimental arguments as a possible trigger for migraine, is demonstrated for the first time during spontaneous attacks. |
| | |
Authors:
|
Marie Denuelle; Nelly Fabre; Pierre Payoux; Francois Chollet; Gilles Geraud |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Headache Volume: 47 ISSN: 0017-8748 ISO Abbreviation: Headache Publication Date: 2007 Nov-Dec |
Date Detail:
|
Created Date: 2007-12-06 Completed Date: 2008-03-27 Revised Date: 2009-02-02 |
Medline Journal Info:
|
Nlm Unique ID: 2985091R Medline TA: Headache Country: United States |
Other Details:
|
Languages: eng Pagination: 1418-26 Citation Subset: IM |
Affiliation:
|
Neurology Service, Rangueil Hospital, Toulouse Cedex 9, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Brain Mapping* Brain Stem / drug effects, physiopathology, radionuclide imaging Female Humans Hypothalamus / drug effects, physiopathology*, radionuclide imaging Male Middle Aged Migraine Disorders / drug therapy, pathology* Positron-Emission Tomography / methods Sumatriptan / therapeutic use Vasoconstrictor Agents / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Vasoconstrictor Agents; 103628-46-2/Sumatriptan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in chil...
Next Document: Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine.